These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16490450)

  • 1. Effects of statins on renal function.
    Agarwal R
    Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin safety: lessons from new drug applications for marketed statins.
    Jacobson TA
    Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
    Verhulst A; D'Haese PC; De Broe ME
    J Am Soc Nephrol; 2004 Sep; 15(9):2249-57. PubMed ID: 15339974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of statins on preservation of kidney function in patients with coronary artery disease.
    Tonelli M
    Curr Opin Cardiol; 2006 Nov; 21(6):608-12. PubMed ID: 17053412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues.
    Campese VM; Ku E; Bigazzi R; Bianchi S
    J Nephrol; 2011; 24(5):550-3. PubMed ID: 21887675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin therapy in patients with chronic kidney disease: to use or not to use.
    Steinmetz OM; Panzer U; Stahl RA; Wenzel UO
    Eur J Clin Invest; 2006 Aug; 36(8):519-27. PubMed ID: 16893373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of statins in chronic kidney disease (CKD): friend or foe?
    Kassimatis TI; Konstantinopoulos PA
    Pharmacol Ther; 2009 Jun; 122(3):312-23. PubMed ID: 19351546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Statins in patients with renal failure--the current therapeutic status].
    Filipiak KJ; Zawadzka-Byśko M
    Przegl Lek; 2005; 62 Suppl 2():51-4. PubMed ID: 16623120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of statins in heart failure.
    Gullestad L; Oie E; Ueland T; Yndestad A; Aukrust P
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():35-40. PubMed ID: 18001320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence?
    Jenkins M; Goldsmith D
    Curr Opin Cardiol; 2012 Jul; 27(4):429-40. PubMed ID: 22678410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of statins.
    Brown WV
    Curr Opin Lipidol; 2008 Dec; 19(6):558-62. PubMed ID: 18957877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of statin-associated proteinuria.
    Tiwari A
    Drug Discov Today; 2006 May; 11(9-10):458-64. PubMed ID: 16635810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of statins on renal function.
    Agarwal R
    Mayo Clin Proc; 2007 Nov; 82(11):1381-90. PubMed ID: 17976359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins in patients with chronic kidney disease: why, who and when?
    Gluba A; Rysz J; Banach M
    Expert Opin Pharmacother; 2010 Nov; 11(16):2665-74. PubMed ID: 20977401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert commentary: the safety of fibrates in lipid-lowering therapy.
    Brown WV
    Am J Cardiol; 2007 Mar; 99(6A):19C-21C. PubMed ID: 17368273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.
    Sidaway JE; Davidson RG; McTaggart F; Orton TC; Scott RC; Smith GJ; Brunskill NJ
    J Am Soc Nephrol; 2004 Sep; 15(9):2258-65. PubMed ID: 15339975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.